In its eagerness to take on the likes of Novartis AG’s oral multiple sclerosis treatment Gilenya (fingolomod), Teva Neuroscience Inc. prepared an exhibit for the American Academy of Neurology meeting last year inaccurately listing a number of risks that it said its relapsing-remitting MS drug Copaxone (glatiramer acetate) doesn’t have but other MS drugs do, FDA’s Office of Prescription Drug Promotion says in a warning letter.
The offending exhibit panels included a table suggesting “that Copaxone is not associated with immunosuppression/infections, decrease in pulmonary...
